Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Beauty Health (SKIN) EBITDA Margin (2021 - 2025)

Beauty Health (SKIN) has disclosed EBITDA Margin for 5 consecutive years, with 15.02% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 669.0% to 15.02% in Q3 2025 year-over-year; TTM through Sep 2025 was 3.25%, a 446.0% increase, with the full-year FY2024 number at 9.88%, up 1490.0% from a year prior.
  • EBITDA Margin was 15.02% for Q3 2025 at Beauty Health, down from 29.85% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 41.52% in Q1 2022 to a low of 76.9% in Q3 2023.
  • A 5-year average of 7.62% and a median of 7.58% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -7497bps in 2023, then soared 5520bps in 2024.
  • Beauty Health's EBITDA Margin stood at 26.51% in 2021, then soared by 122bps to 5.96% in 2022, then crashed by -227bps to 7.58% in 2023, then plummeted by -114bps to 16.25% in 2024, then increased by 8bps to 15.02% in 2025.
  • Per Business Quant, the three most recent readings for SKIN's EBITDA Margin are 15.02% (Q3 2025), 29.85% (Q2 2025), and 12.89% (Q1 2025).